ReviewCurrent pain and headache reports2026
Meaningful Measurable Quality Outcomes in Headache Management.
Review in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewIn this review, we explore the multitude of metrics used to measure the impact of acute and preventive treatments for headache disorders. These measurements seek to quantify the headache experience and changes in that experience through not only pure numerical measures of headache characteristics but also computed patient-reported outcome measures, assessments of participation in activities, and economic evaluations. RECENT
findingsThe 2018-2023 release of CGRP-targeted therapies provided ample opportunity to showcase the current array of outcome metrics. Notable measures include the impact of treatment on physical activity and the change in comorbid symptoms after initiation of effective headache preventive medications. As headache therapeutics continue to advance, finding the best way to measure the benefit of these treatments allows clinicians to select the optimal treatment for their patients.
Indexed as
Identifiers
42726340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.